SOLA Biosciences has shared new preclinical proof-of-concept data for SOL-257, an experimental gene therapy aimed at addressing a key biological driver of ALS. The therapy is designed to reduce the harmful effects of misfolded TDP-43, a protein linked to nerve cell damage in many people with the disease. By targeting